Articles with public access mandates - Lajos PusztaiLearn more
OverallNIHSusan G. KomenCancer Research UKDoDDFGEuropean CommissionNHMRCOTKAMRCGovernment of SpainAIRC Foundation for Cancer Research in ItalyFNRSHEANIHRWellcomeKWFGovernment of ItalyCPRITVASFIEPSRCANRSCLSNSFHHMINSFCNWOBreast Cancer Now, UKNSFFWFCCSCASINSERMState of CalifoniaNKFIUK Research & InnovationNCNRoyal Society UKOICR
Not available anywhere: 18
Gene expression profiling in breast cancer: classification, prognostication, and prediction
JS Reis-Filho, L Pusztai
The Lancet 378 (9805), 1812-1823, 2011
Mandates: Cancer Research UK
Immunotherapy and targeted therapy combinations in metastatic breast cancer
FJ Esteva, VM Hubbard-Lucey, J Tang, L Pusztai
The lancet oncology 20 (3), e175-e186, 2019
Mandates: US National Institutes of Health, Susan G. Komen
Challenges translating breast cancer gene signatures into the clinic
B Weigelt, L Pusztai, A Ashworth, JS Reis-Filho
Nature reviews Clinical oncology 9 (1), 58-64, 2012
Mandates: Cancer Research UK
HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer
F Andre, C Mazouni, C Liedtke, SW Kau, D Frye, M Green, ...
Breast cancer research and treatment 108, 183-190, 2008
Mandates: German Research Foundation
New Therapeutic Strategies for Triple-Negative Breast Cancer.
B Szekely, ALM Silber, L Pusztai
Oncology (08909091), 2017
Mandates: Susan G. Komen
Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer …
P Sharma, E Rodler, WE Barlow, J Gralow, SL Huggins-Puhalla, ...
Journal of Clinical Oncology 38 (15_suppl), 1001-1001, 2020
Mandates: US National Institutes of Health
First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations
T Iwamoto, JS Lee, G Bianchini, RE Hubbard, E Young, J Matsuoka, ...
Breast cancer research and treatment 130, 155-164, 2011
Mandates: US National Institutes of Health
Unvalidated antibodies and misleading results
D Rimm, K Schalper, L Pusztai
Breast cancer research and treatment 147, 457-458, 2014
Mandates: US National Institutes of Health
Bone density screening in postmenopausal women with early-stage breast cancer treated with aromatase inhibitors
J Stratton, X Hu, PR Soulos, AJ Davidoff, L Pusztai, CP Gross, ...
Journal of Oncology Practice 13 (5), e505-e515, 2017
Mandates: US National Institutes of Health
Standardization efforts enabling next-generation sequencing and microarray based biomarkers for precision medicine
Y Zheng, T Qing, Y Song, J Zhu, Y Yu, W Shi, L Pusztai, L Shi
Biomarkers in medicine 9 (11), 1265-1272, 2015
Mandates: National Natural Science Foundation of China
Impact of anti-HER2 therapy alone and with weekly paclitaxel on the ovarian reserve of young women with HER2-positive breast cancer
M Lambertini, M Ceppi, RA Anderson, DA Cameron, M Bruzzone, ...
Journal of the National Comprehensive Cancer Network 21 (1), 33-41. e16, 2023
Mandates: UK Medical Research Council, Government of Italy, AIRC Foundation for Cancer …
A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low-and high-risk prognostic categories
B Szekely, T Iwamoto, AM Szasz, Y Qi, J Matsuoka, WF Symmans, ...
Breast cancer research and treatment 138, 691-698, 2013
Mandates: Cancer Research UK, UK Medical Research Council
Building networks with microarray data
BM Broom, W Rinsurongkawong, L Pusztai, KA Do
Statistical methods in molecular biology, 315-343, 2010
Mandates: US National Institutes of Health
Associations amongst genes, molecules, cells, and organs in breast cancer metastasis
SD Nathanson, LC Dieterich, XHF Zhang, DA Chitale, L Pusztai, ...
Clinical & experimental metastasis, 1-21, 2023
Mandates: US Department of Defense, US National Institutes of Health, German Research …
Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer
V Gunasekharan, HK Lin, M Marczyk, A Rios-Hoyo, GE Campos, NL Shan, ...
Breast Cancer Research and Treatment, 1-15, 2024
Mandates: National Science Centre, Poland
Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast Cancer
M Kok, RJ Gielen, S Adams, JK Lennerz, P Sharma, S Loibl, E Reardon, ...
Journal of Clinical Oncology, JCO. 24.00372, 2024
Mandates: Netherlands Organisation for Scientific Research
Treatment efficacy score: a better surrogate for arm-level survival differences in neoadjuvant breast cancer trials?
RJ Chehayeb, A Kahn, L Pusztai
Future Oncology 19 (28), 1945-1951, 2023
Mandates: Susan G. Komen
Gene Selection for the Identification of Biomarkers in High-Throughput Data
J Jeong, M Vannucci, KA Do, B Broom, S Kim, N Sha, M Tadesse, K Yan, ...
Bayesian Modeling in Bioinformatics, 233, 2010
Mandates: US National Institutes of Health
Available somewhere: 208
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
C Liedtke, C Mazouni, KR Hess, F André, A Tordai, JA Mejia, ...
Journal of clinical oncology 26 (8), 1275-1281, 2008
Mandates: German Research Foundation
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
GM Frampton, A Fichtenholtz, GA Otto, K Wang, SR Downing, J He, ...
Nature biotechnology 31 (11), 1023-1031, 2013
Mandates: US National Institutes of Health, Austrian Science Fund, Wellcome Trust
Publication and funding information is determined automatically by a computer program